ArticleCancers2022

Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide.

Takeyoshi Eda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.